WO2010081262A1 - 一种治疗糖尿病肾病的药物组合物及其制备方法和应用 - Google Patents
一种治疗糖尿病肾病的药物组合物及其制备方法和应用 Download PDFInfo
- Publication number
- WO2010081262A1 WO2010081262A1 PCT/CN2009/000343 CN2009000343W WO2010081262A1 WO 2010081262 A1 WO2010081262 A1 WO 2010081262A1 CN 2009000343 W CN2009000343 W CN 2009000343W WO 2010081262 A1 WO2010081262 A1 WO 2010081262A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxy
- methoxycoumarin
- hydroxycoumarin
- pharmaceutical composition
- diabetic nephropathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to the field of traditional Chinese medicine and, in particular, to a pharmaceutical composition for treating diabetic nephropathy, and a preparation method and application thereof. Background technique
- Diabetic nephropathy is one of the major complications of diabetes and has become the leading cause of end-stage renal failure in Western countries.
- Cortex Mori is the dry root bark of the mulberry plant sangori/s alba L., which is sweet and cold. It has the functions of relieving lung and relieving asthma, diminishing water and swelling, and treating lung heat and cough, edema and fullness of urine. Less, facial edema, recent pharmacological studies have shown that mulberry bark has the effects of lowering blood sugar, blood pressure, diuresis, antitussive and antiasthmatic, anti-HIV and anti-tumor activity. Since the 1970s, some scholars have isolated and confirmed the hypoglycemic component 1-deoxynojirimycin from mulberry bark.
- An object of the present invention is to provide a pharmaceutical composition for treating diabetic nephropathy and a preparation method thereof, wherein the active ingredient of the pharmaceutical composition is a coumarin substance.
- a pharmaceutical composition for treating diabetic nephropathy comprising at least one of 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin as an active ingredient, and a conventional pharmaceutical carrier, said activity
- the weight percentage of the ingredients is
- the active ingredient is present in an amount of from 5 to 70% by weight.
- the pharmaceutical composition consists of 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin as active ingredients, and a conventional pharmaceutical carrier, 7-hydroxycoumarin: 7-hydroxyl
- the weight ratio of 6-methoxycoumarin is 1:4-4:1.
- the pharmaceutical carrier of the present invention refers to a conventional pharmaceutical carrier in the pharmaceutical field, such as a diluent, an excipient such as water, a filler such as starch, lactose or sucrose, etc.; a binder such as a cellulose derivative , alginate, gelatin and polyvinylpyrrolidone; wetting agents such as glycerin; disintegrants such as agar, calcium carbonate and sodium hydrogencarbonate; absorption enhancers such as quaternary ammonium compounds; surfactants such as hexadecanol; adsorption carriers such as kaolin And soap clay; lubricants such as talc, calcium and magnesium stearate, and polyethylene glycol. It is also possible to add other adjuvants such as flavoring agents, sweeteners and the like to the composition.
- a diluent such as a diluent, an excipient such as water, a filler such as starch, lactose or suc
- the pharmaceutical composition of the present invention can be prepared into a conventional dosage form by a conventional preparation method, and the conventional preparation forms are mainly oral preparations, including tablets, capsules, granules, dropping pills, oral liquids and the like.
- the dosage of the pharmaceutical composition of the present invention may be adjusted depending on the particular mode of administration, the severity of the condition, and the like. 'In general, the reference dose for clinical oral use is 10 to 70 mg/d.
- a method for preparing a pharmaceutical composition for treating diabetic nephropathy wherein at least one of 7-hydroxycoumarin or 7-hydroxy-6-methoxycoumarin as an active ingredient is mixed with a conventional pharmaceutical carrier, That is.
- the pharmaceutical composition of the present invention can be produced according to a conventional production method in the field of pharmacy.
- the active ingredient is mixed with a plurality of carriers and then formulated into the desired dosage form.
- the present invention also provides the use of 7-hydroxycoumarin and/or 7-hydroxy-6-methoxycoumarin for the preparation of a medicament for the treatment of diabetic nephropathy.
- the present invention proves for the first time that the coumarin substance extracted from mulberry bark has the function of lowering blood sugar, and provides a new therapeutic candidate drug for patients with diabetes and its complications.
- the pharmaceutical composition of the invention has better therapeutic effect on diabetic nephropathy than the water extract of mulberry white skin, and the active ingredient is clear, the quality is easy to control, and the traditional Chinese medicine has unclear active ingredients, difficult quality control, and certain Disadvantages such as toxic side effects.
- the pharmaceutical composition of the present invention is rich in raw materials and can be processed into oral dosage forms such as dropping pills, granules, tablets, etc., and is convenient to use.
- the pharmaceutical composition of the present invention has a remarkable effect of treating and preventing glomerular damage in diabetes, because it can significantly prevent the increase of serum creatinine in diabetes, significantly reduce the urine volume and urine protein of diabetic rats, and lower the renal index. It shows that it has a significant preventive effect on diabetic nephropathy.
- Figure 1 shows the hypertrophic changes of rat mesangial cells under high glucose culture with 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin (HE, 200X);
- A normal control group
- B glucose (25mm 0 l/L) group
- C mulberry white water extract (0. lg/L)
- D 7-hydroxycoumarin ( ⁇ /L)
- E 7-hydroxycoumarin (0. mol/L)
- F 7-hydroxycoumarin (0. ⁇ /L)
- G 7-hydroxy-6-methoxycoumarin ( ⁇ /L)
- H 7-hydroxy-6-methoxycoumarin (0.
- Figure 2 is the extracellular matrix proliferation of rat mesangial cells cultured in high glucose culture with 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin (PAS, 200X);
- A normal control group
- B glucose (25mmol/L) group
- C mulberry white water extract (0. lg/L)
- D 7-hydroxycoumarin ( ⁇ mol/L)
- E 7-hydroxycoumarin (0. ⁇ /L)
- F 7-hydroxycoumarin (0. ⁇ /L)
- G 7-hydroxy-6-methoxycoumarin (1Hmol/L)
- H 7-hydroxy-6-methoxycoumarin (0.
- Figure 3 is a rat glomerular mesangial cell cultured in high glucose by 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin The effect of CTGF expression (CTGF, 200X);
- A normal control group
- B glucose (25mmol/L) group
- C negative control (without CTGF antibody);
- 0 mulberry white water extract (O.lg/L);
- E 7-hydroxy scent Bean ( ⁇ /L);
- F 7-hydroxycoumarin (0. ⁇ /L);
- G 7-hydroxycoumarin ( ⁇ . ⁇ );
- ⁇ 7-hydroxy-6-methoxy Beans ( ⁇ /L);
- I 7-hydroxy-6-methoxycoumarin (0.
- the coumarin compounds for the preparation of a medicament for treating diabetic nephropathy according to the present invention are 7-hydroxycoumarin ( ⁇ ) and 7-hydroxy-6-methoxycoumarin ( ⁇ ), and their chemical structures are as follows:
- Example 3 Preparation of the pharmaceutical composition capsule of the present invention (active ingredient is 7-hydroxy-6-methoxycoumarin) The steps are as follows:
- Example 4 Preparation of the pharmaceutical composition dropping pill of the present invention (active ingredient is 7-hydroxycoumarin)
- Example 5 Preparation of a pharmaceutical composition tablet of the invention (active ingredient is 7-hydroxycoumarin or 7-hydroxy-6-methoxycoumarin)
- Each tablet contains the following ingredients -
- Preparation method the active ingredient, lactose and starch are mixed, moistened with water, the wetted mixture is sieved and dried, sieved, magnesium stearate is added, and then the mixture is compressed, each tablet weighs 240 mg, active ingredient The content is 12 mg.
- the tablet is useful for the treatment of hyperurinopathy and diabetic nephropathy.
- Example 6 Preparation of Dispersible Tablets of Pharmaceutical Compositions of the Invention (The active ingredients are 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin)
- Preparation method 7-hydroxycoumarin in the active ingredient is 14g, and 7-hydroxy-6-methoxycoumarin is 56g, the active ingredient and the microcrystalline cellulose are mixed, and the water is wetted to form a soft material.
- the wetted mixture was granulated, passed through a 20 mesh sieve, dried at 80 ° C, sieved, and then the mixture was compressed, each tablet weighing 70.4 mg, and the active ingredient content was 70 mg.
- This product is used orally for the treatment of diabetic nephropathy and has a good effect.
- the present invention evaluates the effects of 7-hydroxycoumarin and/or 7-hydroxy-6-methoxycoumarin on rat mesangial cells cultured in high glucose and db
- Test example 1
- a specific symptom of diabetic nephropathy is an increase in extracellular matrix in the mesangial area resulting in mesangial matrix sclerosis.
- Mesangial cells are the main components of the glomerular mesangial membrane. They have multiple functions of contraction, endocrine, division and proliferation, immunity and phagocytosis, and play an important role in mediating the physiological function of glomeruli. Therefore, mesangial cells in a high-concentration glucose culture environment are useful models for studying the matrix of diabetic glomerulosclerosis.
- mulberry white (Cotex Mori), chopped and ground into powder, add 10 times water and reflux for three times, each time for 2 hours, combine the extracts, concentrate under reduced pressure to a certain volume, and set aside.
- Rat glomerular mesangial cells in logarithmic growth phase were prepared as single cell suspension (5 ⁇ 10 4 cells/ml) in DMEM medium containing 5% newborn calf serum, and 1 ml/well was inoculated in advance. The 24-well plate of the slide, the number of cells is 5 X 10 4 /well. After incubating for 24 h at 37 ° C in a 5% CO 2 incubator, the serum-free DMEM medium was used and cultured for 24 h (synchronized).
- the cell supernatant was discarded, and each well was added with DMF medium 900 ⁇ 1 and ⁇ different concentrations of glucose containing 5% newborn calf serum, and each concentration was set to 3 replicates, and cultured in an incubator for 24h, 48h, 72h, 96h, respectively.
- HE staining and PAS staining were used to observe the modeling. The results showed that 25 mM glucose was the best when cultured for 48 h, which was used as the modeling condition of this experiment.
- the normal control group was supplemented with 1 ml of DEME medium, and the high glucose group was supplemented with 900 ⁇ l of DMEM medium and ⁇ glucose (final concentration of 25 mmol/L).
- Three replicates were set in each group, and then incubated for 48 hours at 37 ° C in a 5% CO 2 incubator. After the cells were covered with slides, the cells were removed and fixed, and stained and immunohistochemical stained.
- CTGF staining procedure was as follows: 4% paraformaldehyde fixed cell slides for 30 min; new endogenous horseradish peroxidase was inactivated with methanol solution containing 3% 0 2 for 10 min, washed with distilled water for 3 times; 5% BSA blocked non-specific The antigen was added for 20 minutes; CTGF-anti (1:500) was added dropwise, 4° ⁇ overnight, PBS ( P H7.4) was washed 3 times for 2 min each time; biotinylated goat anti-mouse antibody (secondary antibody) was added dropwise. Leave at 37 ° C for 30 min, wash PBS (pH 7. 4) 3 times, each time 2 min; add reagent SABC, 37.
- the hypertrophic changes, extracellular matrix proliferation and CTGF expression of rat mesangial cells were observed under microscope.
- rat glomerular mesangial cells are obviously hypertrophied in high glucose (25mmol/L) culture; water extract of mulberry bark, single use and combination of 7-hydroxycoumarin and 7-light base -6-methoxycoumarin can significantly inhibit the hypertrophy of glomerular mesangial cells induced by high glucose culture, and the effect of monomeric compounds is significantly better than that of total aqueous extracts, and the combined effect is better than single use or equivalent.
- Db mice B6 mice (provided by the Experimental Animal Center of Southern Medical University); Accu-Chek Advantage blood glucose meter (Roche Diagnostics, USA); SPECTRA maxl90 (American AD); creatinine assay kit, Coomassie brilliant blue assay Kit (Nanjing Institute of Bioengineering). 2. Experimental method
- mice were kept in a laminar flow cabinet, free to eat, water, daily water replacement, litter, keep the cage clean and dry, and fix the water, feed, and litter weight, alternate lighting for 12 hours. All utensils and food are disinfected daily.
- mice of 8 weeks old were randomly divided into 11 groups, 10 in each group: model group, mulberry white water extract group (dose 2000mg crude drug/kg), 7-hydroxycoumarin group (dose) 0.5, 1.0, 2. Omg/kg) and 7-hydroxy-6-methoxycoumarin group (dose 0.5, 1.0, 2. Omg/kg, respectively); 7-hydroxycoumarin and 7- Hydroxy-6-methoxycoumarin combination (dose 0.6:0.3, 0.5:0.5, 0.3:0.6rag/kg, respectively) o
- Each group was given the same drug or saline 0.4 ml for 5 weeks for the same time.
- db diabetic nephropathy mice increased after 5 weeks; water extract of mulberry bark, single use and combination of 7-hydroxycoumarin and 7-hydroxy-6-methoxy
- the coumarin can significantly reduce the kidney weight and kidney index of db
- the combined effect is slightly better than single use.
- Table 4 Effects of 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin on kidney weight and renal index in db
- db diabetic nephropathy mice ( ⁇ soil S;, n 10)
- Kidney weight g
- Kidney index %.
- Normal control group 0.26 ⁇ 0.04* 7.0 ⁇ 1.2**
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010546200A JP2011510098A (ja) | 2009-01-16 | 2009-03-31 | 糖尿病性腎症のための医薬組成物、並びにその調製及び適用 |
EP09833902A EP2450038A4 (en) | 2009-01-16 | 2009-03-31 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETIC NEUROPATHY AND MANUFACTURING AND USE METHODS |
US12/823,305 US20100267819A1 (en) | 2009-01-16 | 2010-06-25 | Pharmaceutical composition for diabetic nephropathy and its preparation and application |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100367151A CN101780070B (zh) | 2009-01-16 | 2009-01-16 | 一种治疗糖尿病肾病的药物组合物及其制备方法 |
CN200910036715.1 | 2009-01-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/823,305 Continuation US20100267819A1 (en) | 2009-01-16 | 2010-06-25 | Pharmaceutical composition for diabetic nephropathy and its preparation and application |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010081262A1 true WO2010081262A1 (zh) | 2010-07-22 |
Family
ID=42339384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/000343 WO2010081262A1 (zh) | 2009-01-16 | 2009-03-31 | 一种治疗糖尿病肾病的药物组合物及其制备方法和应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100267819A1 (zh) |
EP (1) | EP2450038A4 (zh) |
JP (1) | JP2011510098A (zh) |
KR (1) | KR20100103538A (zh) |
CN (1) | CN101780070B (zh) |
HK (1) | HK1145452A1 (zh) |
WO (1) | WO2010081262A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101188886B1 (ko) | 2010-10-22 | 2012-10-09 | 삼성에스디에스 주식회사 | 유전 정보 관리 시스템 및 방법 |
CN102846598A (zh) * | 2012-08-03 | 2013-01-02 | 广州康臣药物研究有限公司 | 香豆素在制备AGEs形成抑制剂中的应用 |
CN103948586B (zh) * | 2014-05-13 | 2015-11-25 | 陈金杰 | 一种治疗失眠症的药物组合物及其应用 |
CN106324161B (zh) * | 2016-10-24 | 2017-11-14 | 广州康臣药物研究有限公司 | 治疗糖尿病肾病的中药组合物的质量检测方法 |
CN107198692A (zh) * | 2017-03-01 | 2017-09-26 | 长沙博海生物科技有限公司 | 五加苷元在制备治疗糖尿病药物中的应用 |
CN110934864A (zh) * | 2019-12-19 | 2020-03-31 | 佛山科学技术学院 | 4-甲基-6,7-二甲氧基香豆素在制备防治糖尿病肾病的药物中的应用 |
CN113975270A (zh) * | 2021-11-23 | 2022-01-28 | 广州康臣药业有限公司 | 香豆素的新应用 |
CN117599043A (zh) * | 2023-11-22 | 2024-02-27 | 中国人民解放军联勤保障部队第九二〇医院 | 二氢异香豆素及其衍生物在制备用于治疗骨科疾病的药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1615847A (zh) * | 2004-10-19 | 2005-05-18 | 中国药科大学 | 东莨菪素在制备防治高尿酸血症药物中的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4616033A (en) * | 1985-03-14 | 1986-10-07 | Lamorna Investments Proprietary Ltd. | 7 hydroxy-coumarin as a treatment for high protein oedemas |
CN1348776A (zh) * | 2000-10-14 | 2002-05-15 | 马有才 | 治疗肾病的胶囊、散、片、丸、口服液及制作方法 |
US6855345B2 (en) * | 2001-11-02 | 2005-02-15 | Morinda, Inc. | Preventative and treatment effects of Morinda citrifolia on diabetes and its related conditions |
CN1201769C (zh) * | 2002-09-19 | 2005-05-18 | 汤婉清 | 治疗糖尿病、肾病的药物 |
CN1506359A (zh) * | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | 新的香豆素酰胺衍生物及其制法和其药物组合物与用途 |
TWI287990B (en) * | 2004-01-08 | 2007-10-11 | Nat Defense Medical Ct | Inhibitors and enhancers of uridine diphosphate-glucuronosyl transferase 2B (UGT2B) |
JP4658512B2 (ja) * | 2004-04-27 | 2011-03-23 | 日本臓器製薬株式会社 | クマリン誘導体及び該誘導体を含有するメイラード反応阻害剤 |
WO2006116814A1 (en) * | 2005-05-02 | 2006-11-09 | Vanadis Bioscience Ltd | Composition and uses thereof |
CN100428934C (zh) * | 2006-09-07 | 2008-10-29 | 中国人民解放军第二军医大学 | 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用 |
US20080145492A1 (en) * | 2006-12-13 | 2008-06-19 | Logsdon Lawrence M | Noni juice composition and process therefor |
-
2009
- 2009-01-16 CN CN2009100367151A patent/CN101780070B/zh active Active
- 2009-03-31 KR KR1020107014242A patent/KR20100103538A/ko not_active Application Discontinuation
- 2009-03-31 JP JP2010546200A patent/JP2011510098A/ja active Pending
- 2009-03-31 WO PCT/CN2009/000343 patent/WO2010081262A1/zh active Application Filing
- 2009-03-31 EP EP09833902A patent/EP2450038A4/en not_active Withdrawn
-
2010
- 2010-06-25 US US12/823,305 patent/US20100267819A1/en not_active Abandoned
- 2010-12-21 HK HK10111953.0A patent/HK1145452A1/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1615847A (zh) * | 2004-10-19 | 2005-05-18 | 中国药科大学 | 东莨菪素在制备防治高尿酸血症药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2011510098A (ja) | 2011-03-31 |
CN101780070A (zh) | 2010-07-21 |
CN101780070B (zh) | 2012-08-22 |
US20100267819A1 (en) | 2010-10-21 |
EP2450038A4 (en) | 2012-05-30 |
HK1145452A1 (en) | 2011-04-21 |
KR20100103538A (ko) | 2010-09-27 |
EP2450038A1 (en) | 2012-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010081262A1 (zh) | 一种治疗糖尿病肾病的药物组合物及其制备方法和应用 | |
US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
CN101396421A (zh) | 具有雌激素样作用的中药组合物及其应用 | |
KR101214751B1 (ko) | 당뇨병성 신장질환의 예방 및 치료용 약학 조성물 및 그의 제조방법 | |
CN101897776A (zh) | 海棠提取物及根皮苷的新用途 | |
DK2120924T3 (en) | Anti-diabetic honey bush-extract | |
CN103766901A (zh) | 一种穿心莲丙素在制备减肥食品或药品中的应用 | |
CN108159204B (zh) | 一种具有解毒保肝作用的藏药组合物 | |
JP5352598B2 (ja) | 糖尿病性腎症のための医薬組成物、並びにその調製及び適用 | |
KR20040060808A (ko) | 혼합 생약재를 이용한 비만 억제용 조성물 | |
CN102349956A (zh) | 一种润燥止痒复方的提取物及其制剂 | |
CN117731709B (zh) | 一种治疗前列腺炎、前列腺增生的药物及其制备方法与应用 | |
CN115120631B (zh) | 一种治疗痛风及高尿酸血症的药物组合物及其制备方法 | |
CN101775026B (zh) | 螺环生物碱化合物及含其的药物组合物及其制备方法和应用 | |
CN106046071A (zh) | 一种苯丙素类化合物的制备方法 | |
CN107080761B (zh) | 腊梅属植物抗伪狂犬病毒的用途 | |
CN105732736A (zh) | 一种苯丙素类化合物的制备方法 | |
CN105708845A (zh) | 一种苯丙素类化合物及其药学上可接受的盐在制备治疗炎症性疾病的药物中的应用 | |
CN106046072A (zh) | 苯丙素类化合物及其药学上可接受的盐和药物组合物 | |
CN106046073B (zh) | 一种苯丙素类化合物的制备方法 | |
CN117883456A (zh) | 川牛膝甾酮类化合物在制备治疗类风湿关节炎的药物中的用途 | |
CN113876844A (zh) | 一种用于治疗慢性气管炎的纯中药藏药及其制备方法和应用 | |
CN116726097A (zh) | 一种用于减肥的中药组合物及其制备方法和应用 | |
CN114699478A (zh) | 一种治疗甲状腺肿的中药组合物及其应用 | |
CN110507700A (zh) | 一种含青蒿素与火把花的药物组合物、制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2010546200 Country of ref document: JP Ref document number: 3955/CHENP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20107014242 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009833902 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09833902 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |